Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma

布仑妥昔单抗维多汀 无容量 医学 内科学 耐火材料(行星科学) 肿瘤科 移植 淋巴瘤 达卡巴嗪 胃肠病学 化疗 霍奇金淋巴瘤 癌症 免疫疗法 物理 天体生物学
作者
Perla R. Colunga‐Pedraza,Edgar Coronado-Alejandro,Fernando De La Garza,Eliezer Tomas Gomez Gomez,Andrés Gómez‐De León,Julia Esther Colunga Pedraza,Cesar Homero Gutiérrez‐Aguirre,Olga Graciela Cantú Rodríguez,David Gómez‐Almaguer
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (Supplement 1): 4534-4534
标识
DOI:10.1182/blood-2021-153267
摘要

Abstract Background: Up to one-third of patients with Hodgkin lymphoma (HL) are not responsive to first-line therapy or eventually relapse. New drugs, including anti-PDL1 (i.e., nivolumab) and monoclonal antibodies (i.e., brentuximab vedotin (BV)), have changed the landscape in the treatment of HL. However, the financial toxicity associated with these new drugs is worrisome and are practically inaccessible to most patients living in low-middle income countries. The approved dose of nivolumab in refractory classical Hodgkin Lymphoma (HL) is 3 mg/kg, but lower doses have demonstrated efficacy. Objective: To assess the efficacy of low-dose nivolumab at a fixed dose of 40 mg, 100 mg, or 140 mg in combination with BV 1.8 mg/kg every three weeks in patients with relapsed or refractory (R/R) HL. Methods: We conducted a retrospective analysis of adults with R/R HL who received BV at 1.8 mg/kg and low-dose nivolumab at a fixed dose of 40 mg, 100 mg, or 140 mg IV every three weeks. Patients were routinely offered the highest dose possible that could be afforded for at least 4 cycles, as treatment costs were covered out of pocket. We calculated treatment responses, and overall survival (OS), and progression-free survival (PFS) with the Kaplan-Meier method. Results: A total of 10 patients (50% male, median of age 26.5 years (15-50)) with R/R HL were included; n=7 relapsed and n=3 refractory patients. Median follow-up was 11.5 months (range, 5-18) (antes o después del BV/nivo?). The median previous lines of treatment were three (range, 1-4) and regimens were ESHAP (2, 20%), IGEV (3, 30%)), CGEV (1, 10%), ICE (3, 30%), and allogenic transplantation (1, 10%). Six patients (60%) had received radiotherapy (median dose: 21.5 Gy, range: 20-25). Five patients (50%) received 40 mg of nivolumab, n=3 100 mg (30%) and n=2 140mg (20%). The median dose per cycle was 0.93 mg/kg (range, 0.48-1.9 mg/kg). After a median of 4 (range, 4-8) cycles of low-dose nivolumab + BV the overall response rate was 80% (n=8); five obtained a complete response (CR) (50%) and n=3 a partial response (30%) . One patient (10%) had stable disease, and the other progressed (10%). Grade 1 or 2 adverse events occurred in n=6 patients (60%), including neuropathy (n=2), grade 1 leucopenia (n=3), fever (n=1), and myalgia (n=1). No grade III or IV adverse events were reported. One-year OS and PFS was 83.3%. Transplant consolidation was conducted in six cases (60%) (three autologous and three haploidentical), three are awaiting transplantation and one relapsed after achieving CR before transplant conditioning. One patient died on day +21 after haploidentical transplantation in the context of progressive disease. Conclusion: A short course of low-dose nivolumab and BV showed remarkable efficacy, achieving response in most patients with minimal toxicity and allowed patients with R/R HL who could not afford standard doses to undergo transplantation. The real-world safety and efficacy of low-dose nivolumab and BV should be further addressed in more extensive prospective studies. Figure 1 Figure 1. Disclosures Gomez-De Leon: ASH: Research Funding; Sanofi: Honoraria; Novartis: Honoraria; Abbvie: Honoraria. Gomez-Almaguer: Janssen: Honoraria, Speakers Bureau; Bristol-Myers-Squibb: Honoraria, Speakers Bureau; Roche: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
敬老院N号应助洋洋采纳,获得30
2秒前
Youu发布了新的文献求助10
3秒前
De.完成签到 ,获得积分10
3秒前
飞云发布了新的文献求助10
3秒前
4秒前
5秒前
小胡爱科研完成签到,获得积分10
5秒前
天天快乐应助和谐的敏采纳,获得10
5秒前
6秒前
夜願完成签到,获得积分10
9秒前
研友_VZG7GZ应助Jeffery采纳,获得10
9秒前
9秒前
英姑应助Susan采纳,获得10
9秒前
盐焗小星球完成签到,获得积分10
10秒前
11秒前
超级月饼完成签到,获得积分20
11秒前
爆米花应助小黄人采纳,获得10
11秒前
压缩发布了新的文献求助10
13秒前
吴大宝发布了新的文献求助10
13秒前
超级月饼发布了新的文献求助10
14秒前
16秒前
18秒前
19秒前
19秒前
路过银河发布了新的文献求助10
22秒前
23秒前
23秒前
liqian发布了新的文献求助10
24秒前
25秒前
JJJJJJJ发布了新的文献求助10
27秒前
小柒柒应助妍宝贝采纳,获得10
27秒前
27秒前
SciGPT应助连安阳采纳,获得10
27秒前
华子的五A替身完成签到,获得积分10
28秒前
小二郎应助我家不住隔壁采纳,获得10
29秒前
桐桐应助可爱的香菱采纳,获得10
29秒前
123发布了新的文献求助10
29秒前
六六完成签到 ,获得积分10
30秒前
沉静蘑菇完成签到,获得积分20
30秒前
德玛西亚完成签到,获得积分10
31秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3051374
求助须知:如何正确求助?哪些是违规求助? 2708662
关于积分的说明 7413751
捐赠科研通 2352869
什么是DOI,文献DOI怎么找? 1245378
科研通“疑难数据库(出版商)”最低求助积分说明 605633
版权声明 595829